Liver resection for liver metastasis of colorectal cancer
Conditions
Interventions
Oral administration of Tegaful/Uracil 200-300mg/m2/day and leucovorin 75mg/day for 5 course (5 weeks of administration followed by 1 week of no administration)
Sponsors
Oita university, faculty of medicine, department gastroenterology and pediatric surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically proven colorectal cancer 2.Case with liver metastasis simultaneously or metachronously 3.No extrahepatic sites of disease 4.Curatively resected metastatic liver tumor 5.Performance status must be Eastern Cooperative Oncology Group (ECOG) 0 or 1 6.Oral intake is possible 7.Adequate bone marrow, hepatic, renal, cardiac and respiratory functions 8.Written informed consent
Exclusion criteria
Exclusion criteria: 1.Active synchronous or metachronous malignancy other than carcinoma in situ 2.Serious postoperative complications 3.Serious coexisting illness A) Uncontrolled diabetes mellitus B) Uncontrolled hypertension C) History of myocardial infarction, unstable angina within 6 months prior to the registration D) Severe pulmonary dysfunction E) Liver cirrhosis 4.Ascites or pleural effusion needed to 5.Positive HBs antigen 6.Bleeding, paralysis, obstruction or ulcer of gastrointestinal tract 7.Pregnant or nursing 8.Severe mental disorders 9.Not suitable for participating in the study for any other Reason by the physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Optimal dose | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event, Overall survival, Disease free survival, Pharmacokinetics | — |
Countries
Japan
Contacts
Public ContactYukio Iwashita
Oita university faculty of medicine Gastroenterological and pediatric surgery
Outcome results
None listed